Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

10.7K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same author

Zebrafish--on the move towards ophthalmological research.

Eye (London, England)·2014
Same author

A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.

Cell death and differentiation·2007
Same author

A subgroup of spinocerebellar ataxias defective in DNA damage responses.

Neuroscience·2007
Same author

The complexity of p53 stabilization and activation.

Cell death and differentiation·2006
Same author

Live cell imaging of heavy-ion-induced radiation responses by beamline microscopy.

Radiation research·2005

Related Experiment Video

Updated: Mar 21, 2026

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.3K

Idebenone for Leber's hereditary optic neuropathy.

N Gueven1

  • 1Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia. nguven@utas.edu.au.

Drugs of Today (Barcelona, Spain : 1998)
|May 18, 2016
PubMed
Summary

Idebenone is the only proven treatment for Leber's hereditary optic neuropathy (LHON). Early treatment with this drug improves retinal cell function, preventing vision loss and promoting recovery.

Keywords:
Genetic disordersIdebenoneInherited mitochondrial respiratory chain diseasesLHONLeber’s hereditary optic neuropathyMetabolic diseases

More Related Videos

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

20.4K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.6K

Related Experiment Videos

Last Updated: Mar 21, 2026

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.3K
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

20.4K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.6K

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Mitochondrial Medicine

Background:

  • Leber's hereditary optic neuropathy (LHON) is a genetic condition causing vision loss.
  • Mitochondrial complex I dysfunction is central to LHON pathogenesis.
  • Currently, few effective treatments exist for LHON.

Purpose of the Study:

  • To evaluate idebenone as a treatment for LHON.
  • To understand the mechanism of action of idebenone in LHON.
  • To determine the optimal timing for idebenone treatment initiation.

Main Methods:

  • Idebenone's molecular mechanism involves bypassing defective mitochondrial complex I.
  • Clinical data supports the efficacy of idebenone in LHON patients.
  • Assessment of functional recovery in retinal ganglion cells.

Main Results:

  • Idebenone is rapidly absorbed, safe, and well-tolerated.
  • It improves energy supply by bypassing the defective mitochondrial complex I.
  • Clinical data suggests early treatment is most effective for vision recovery.

Conclusions:

  • Idebenone is the only clinically proven treatment for LHON.
  • Early intervention with idebenone can prevent vision loss and promote recovery.
  • The drug's mechanism supports its therapeutic role in LHON.